Uso de células mononucleares da medula óssea no tratamento de tendinites induzidas experimentalmente em equinos

Abstract

RESUMOForam induzidas lesões no tendão flexor digital superficial (TFDS) de ambos os membros anteriores de seis equinos, seguidas de implante autólogo de células da fração mononuclear de medula óssea em apenas um membro de cada animal. Os animais foram avaliados por parâmetros clínicos, ultrassonográficos, histopatológico e imunoistoquímico. Paralelamente, realizou-se o cultivo de novas amostras para a caracterização das células utilizando-se marcadores CD34 e CD45 por meio da citometria de fluxo, confirmando a presença de células mesenquimais na fração mononuclear. A caracterização das fibras colágenas tipo I e tipo III no tecido neoformado mostrou melhora na qualidade da cicatrização tendínea dos membros tratados. A terapia com implante autólogo das células da fração mononuclear melhorou a organização tecidual e a sua qualidade, apresentando maior expressão significativa para colágeno tipo I.Palavras-chave: equino, célula-tronco, fração mononuclear, medula óssea, tendão ABSTRACT The present study was developed inducing a lesion in the SDFT of both thoracic limbs of six horses followed by autologous implantation of mononuclear cells from bone marrow in only one

Culture of equine bone marrow mononuclear fraction and adipose tissue-derived stromal vascular fraction cells in different media

“…In horses BMAC has been used to improve cartilage, bone, and tendon repair, with good results (Gutierrez-Nibeyro 2011). Oliveira et al (2011) utilized bone marrow mononuclear fraction cells in the treatment of induced tendinitis in horses and observed improvement in tissue organization, with greater alignment of fibers and higher percentage of non-lesioned area.…”

Autologous implant of bone marrow mononuclear stem-cells as treatment for equine bicipital tendonitis: case report

“…It is important to consider that although this case was conducted differently when compared to animals under experimental conditions (Barreira et al 2008, Oliveira 2008 and also the rehabilitation protocol (Gillis 2004) was not entirely followed, clinical and ultrasonographic findings were considerably satisfactory allowing the horse to return to working activities before the recommended recovery period (6 to 9 months), without lameness recurrence in a follow up period of 15 months as reported by Gutierrez-Nibeyro (2011) andSmith (2010). These results suggest the use of juxtatendinous steroid injection followed by autologous implant of bone marrow mononuclear cells associated to rest and controlled exercise, accelerated tendinous repair, reduced recovery time and allowed successful return to complete working activity of this horse.…”

“…Type 3 collagen fibers are longer but thinner, which results in less resistance to stretching forces leading to recurrent rupture of fibers and tendonitis onsets (Oliveira 2008). This has been considered the primary reason why this type of injury has reserved prognosis to return to working and sports activities and explain its high rates of recurrence and degenerative characteristics (Barreira et al 2008).…”

“…Soft tissues are considered the main cause of lameness referable to this region and the inflammation of the bicipital tendon and its adjacent bursa the most observed injury (Tnibar et al 1999, Reef et al 2004. The presentation of different types of equine tendonitis can be very high, eventually affecting up to 30% of some equine populations (Oikawa andKasashima 2002, Oliveira 2008), but specially bicipital tendonitis is of lower incidence (Bassage and Ross 2011).…”

How to obtain and isolate equine sternal bone marrow mononuclear cells with limited resources

“…From BM, there are two main products that are being currently applied for the treatment of orthopedic injuries in the horse: bone marrow mononuclear cell fraction (BMMNCs), which comprise some hematopoietic progenitor cells, MSCs and monocytes, which can be readily isolated and injected into the lesion; on the other hand, there is the use of cultivated MSCs derived from the mononuclear cells (MNCs) fraction of BM. Both have demonstrated to enhance the repair of soft tissue injuries in horses (Smith et al 2003, Oliveira 2008, Crovace et al 2010, nonetheless, all the described protocols require access to fully equipped and costly laboratory facilities. Besides, obtaining a pure fraction of cultivated MSCs also demands longer time (2-3 weeks) (Fortier andSmith 2008, Kol et al 2013) and higher costs related to cell culture (Owens et al 2011).…”